Trial Search Results

Pharmacogenomic Analysis in Pediatric Acute Lymphoblastic Leukemia

This is a retrospective biobank study evaluating the impact of novel genetic variants in a population of 6-mercaptopurine treated pediatric acute lymphoblastic leukemia patients.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Cipherome, Inc.

Collaborator: Stanford University

Stanford Investigator(s):

Eligibility


Inclusion Criteria:

   - Pediatric acute lymphoblastic leukemia (ALL) subjects

   - Received 6-mercaptopurine

   - Available biobank (bone marrow or blood) sample(s) from which deoxyribonucleic acid
   (DNA) can be extracted

   - White blood cell (WBC) levels

Exclusion Criteria:

   - Pediatric ALL subjects who did NOT receive 6-mercaptopurine

   - No biobank sample

   - No WBC level

Ages Eligible for Study

N/A - 21 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Recruiting